+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

Journal of the National Cancer Institute 88(12): 779-781

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 046280073

Download citation: RISBibTeXText

PMID: 8637038

DOI: 10.1093/jnci/88.12.779

Related references

Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. European Urology 53(1): 6-9, 2007

Clinical evaluation of prostate biopsy parameters: gland volume and elevated prostate-specific antigen level. Radiology 199(1): 159-163, 1996

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology 22(3): 537-556, 2004

Evaluation of prostate-specific antigen as a quantifiable indicator of condom failure in clinical trials. Contraception 60(5): 289-298, 1999

Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. European Urology 39(1): 57-64, 2001

Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1-10 ng/ml. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 96(4): 475-479, 2005

Clinical evaluation of total prostate specific antigen determined with the Qualigen FastPack point of care system. Tumor Biology 24(Suppl. 1): 73, 2003

Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen. European Urology 24(4): 487-491, 1993

Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. Journal of Urology 158(2): 502-504, 1997

The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. Journal of Urology 159(4): 1234-1237, 1998

Clinical evaluation of a two site immunoradiometric assay for prostate specific antigen using monoclonal antibodies tandem r prostate specific antigen. Clinical Chemistry 32(6): 1123, 1986

Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. Journal of Urology 200(4): 758-766, 2018

The clinical usefulness of prostate-specific antigen (PSA) level and age-specific PSA reference ranges for detecting prostate cancer in Chinese. Urologia Internationalis 72(3): 208-211, 2004

Can prostate specific antigen density of the transition zone improve preoperative staging of prostate cancer in patients with serum prostate specific antigen level below 10 NG/ML?. Journal of Urology 161(4 Suppl. ): 247, 1999

The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen level after radiation therapy for prostate cancer. Cancer 72(3): 832-842, 1993